The injection is indicated to treat cancer and is administered intravenously, hindubusinessline.com reported.
The drug in the strengths of 10 mg/ vial and 50 mg/ vial, received approval
The Hindu Business Line quoted Strides Arcolab as saying that the drug belongs to the oncology portfolio licensed to Pfizer in January 2010 for the US market.